[ad_1]
The Oxford Covid-19 vaccine produces an immune response in the elderly as well as the young, according to the manufacturers of the inoculation.
straZeneca Plc has stated that older people receive an immune response from the vaccine.
This statement is positive since the immune system weakens with age and older people are at the highest risk of dying from the virus.
The vaccine, developed by the University of Oxford, also triggers lower adverse responses among the elderly, the drug company has stated.
A company spokesperson said: “It is encouraging to see that immunogenicity responses were similar between older adults and young people and that reactogenicity (reaction to the vaccine) was lower in older adults, where the severity of the COVID- 19 is older.
“The results further strengthen the body of evidence for the safety and immunogenicity of (vaccine) AZD1222.”
AstraZeneca did not provide statistics on its statement.
The company has not yet announced when it will release data from the late-stage phase III trial.
This date will highlight whether the vaccine is successful in large-scale trials, which could allow its approval.
The European Center for Disease Prevention and Control (ECDC) published yesterday (Monday) a report on the key aspects related to the introduction and prioritization of Covid-19 vaccines.
These included a “robust disease surveillance system”, effectiveness and impact studies; active and passive monitoring of adverse events after immunization, solid and timely data on vaccination coverage; evidence-based decision making; legal and regulatory frameworks for vaccine deployment; and ethical and equitable access to a vaccine.
He also noted that there is still a lot of work to ensure that the inoculation is successful.
He stated that “there is currently a lack of certainty and knowledge about the characteristics of Covid-19 vaccines that might be available in the EU / EEA and the UK, as well as the remaining gaps in scientific knowledge of the virus and the disease.”
Therefore, vaccination plans and strategies should “be adapted as more information becomes available,” he added.
“Once Covid-19 vaccines are available, their supply is likely to be limited, at least initially.
“The supply capacity, both initially and over time, will determine the use of the vaccine and the prioritization of delivery.
“Implementation will need to be adjusted accordingly to quickly optimize vaccine allocation and ensure vaccine availability to those most in need.”
The report recommends that access to particular groups be offered as a priority. These include those at risk for severe Covid-19, including essential workers, vulnerable groups, and the elderly.
The document indicated that those who are at “higher risk of further exposure and transmission,” such as younger adults and those working in professional settings, should also be considered in priority groups.
According to the European Medicines Agency (EMA), in the “best case”, the agency would receive clinical data on the most advanced vaccines by the end of 2020.
Communication strategies would need to be developed, the report explained, “to aid vaccine or vaccine acceptability and address vaccine vacillation … Reactive planning is needed for safety threats and public concerns during these. bells”.
The Oxford / AstraZeneca vaccine is expected to be one of the first to gain regulatory approval, along with inoculation from Pfizer and BioNTech.
Online editors
[ad_2]